MedTrace Logo

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

NCT01747538 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 281

Last updated 2016-07-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.

Conditions

  • Uveitis

Interventions

DRUG

Placebo

Solution for subcutaneous injection

DRUG

Dose 1 gevokizumab

Solution for subcutaneous injection

DRUG

Dose 2 gevokizumab

Solution for subcutaneous injection

Sponsors & Collaborators

  • Institut de Recherches Internationales Servier

    collaborator OTHER

  • XOMA (US) LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2016-06-30

Countries

  • United States
  • Argentina
  • Armenia
  • Australia
  • Brazil
  • Canada
  • China
  • France
  • Germany
  • Greece
  • Israel
  • Italy
  • Mexico
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Taiwan
  • Tunisia
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01747538 on ClinicalTrials.gov